NCT06990373

Brief Summary

This cross-sectional study aims to establish reference intervals for iron biomarkers-including serum iron, ferritin, total iron-binding capacity (TIBC), and transferrin saturation (TSAT)-in healthy pregnant women during the first trimester. Additionally, the study will investigate the current prevalence of non-anemic iron deficiency (NAID) in this population. By applying strict inclusion and exclusion criteria to eliminate potential confounding factors, the study seeks to provide a reliable baseline for evaluating iron status and early detection of iron deficiency without anemia among pregnant women.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 12, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 18, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 25, 2025

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 30, 2025

Completed
Last Updated

May 30, 2025

Status Verified

May 1, 2025

Enrollment Period

4 months

First QC Date

May 18, 2025

Last Update Submit

May 24, 2025

Conditions

Keywords

NAIDIDWAIron deficiencyPregnant

Outcome Measures

Primary Outcomes (3)

  • Prevalence of iron supplement using women that has non-anemic iron deficiency in the first trimester

    Non-anemic iron deficiency is defined as hemoglobin ≥ 11 g/dL and transferrin saturation (TSAT) \< 20%. The prevalence will be calculated as the proportion of enrolled pregnant women meeting these criteria

    At baseline (upon enrollment)

  • Prevalence of non iron supplement using women that has non-anemic iron deficiency in the first trimester

    Non-anemic iron deficiency is defined as hemoglobin ≥ 11 g/dL and transferrin saturation (TSAT) \< 20%. The prevalence will be calculated as the proportion of enrolled pregnant women meeting these criteria

    At baseline (upon enrollment)

  • Reference Intervals for Iron Biomarkers in the First Trimester

    Establish reference intervals (2.5th-97.5th percentile) for serum iron, ferritin, TIBC, and TSAT in healthy first-trimester pregnant women meeting inclusion criteria

    At baseline (upon enrollment)

Study Arms (2)

With iron supplement

Pregnant women who are taking iron supplement

Without iron supplement

Pregnant women who are not taking any iron supplement

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Pregnant women

You may qualify if:

  • Pregnant women attending antenatal care, carrying a single live fetus.
  • Systolic blood pressure at the time of examination \< 140 mmHg.
  • Diastolic blood pressure at the time of examination \< 90 mmHg.
  • Body temperature at the time of examination between \>35°C and \<37.5°C.
  • Hemoglobin ≥ 11 g/dL

You may not qualify if:

  • History of diabetes mellitus, hypertension, hemoglobinopathies, leukemia, non-hematologic cancers, systemic lupus erythematosus, Gastrointestinal diseases (Celiac disease, Crohn's disease and ulcerative colitis, Gastric diseases or prior gastrointestinal surgery, Irritable bowel syndrome, etc).
  • Currently on gastric acid-suppressing medications: Proton pump inhibitors (e.g., Omeprazole, Lansoprazole, Esomeprazole...), H2 receptor antagonists (e.g., Ranitidine, Famotidine, Cimetidine...), Positive screening for Treponema pallidum, HBsAg, or HIV.
  • Use of stimulants or tobacco smoking.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hung Vuong Hospital

Ho Chi Minh City, Ho Chi Minh, 70000, Vietnam

RECRUITING

Related Publications (5)

  • Auerbach M, Abernathy J, Juul S, Short V, Derman R. Prevalence of iron deficiency in first trimester, nonanemic pregnant women. J Matern Fetal Neonatal Med. 2021 Mar;34(6):1002-1005. doi: 10.1080/14767058.2019.1619690. Epub 2019 Jun 3.

    PMID: 31154873BACKGROUND
  • Fisher AL, Nemeth E. Iron homeostasis during pregnancy. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1567S-1574S. doi: 10.3945/ajcn.117.155812. Epub 2017 Oct 25.

    PMID: 29070542BACKGROUND
  • Daru J, Allotey J, Pena-Rosas JP, Khan KS. Serum ferritin thresholds for the diagnosis of iron deficiency in pregnancy: a systematic review. Transfus Med. 2017 Jun;27(3):167-174. doi: 10.1111/tme.12408. Epub 2017 Apr 20.

    PMID: 28425182BACKGROUND
  • Mei Z, Addo OY, Jefferds MED, Flores-Ayala RC, Brittenham GM. Physiologically based trimester-specific serum ferritin thresholds for iron deficiency in US pregnant women. Blood Adv. 2024 Jul 23;8(14):3745-3753. doi: 10.1182/bloodadvances.2024013460.

    PMID: 38781318BACKGROUND
  • Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248. doi: 10.1016/S0140-6736(20)32594-0. Epub 2020 Dec 4.

    PMID: 33285139BACKGROUND

MeSH Terms

Conditions

Iron Deficiencies

Condition Hierarchy (Ancestors)

Iron Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Central Study Contacts

Huan Nguyen Pham, Master of medicine

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
1 Week
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

May 18, 2025

First Posted

May 25, 2025

Study Start

March 12, 2025

Primary Completion

June 30, 2025

Study Completion

August 30, 2025

Last Updated

May 30, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will share

Yes, the investigators plan to share individual participant data (IPD) that underlie the results reported in future publications, including de-identified data on hemoglobin, serum iron, ferritin, TIBC, transferrin saturation (TSAT), maternal demographics (age, BMI, gestational age), and relevant inclusion/exclusion criteria. Data will be available upon reasonable request for research purposes, following approval by the principal investigator and ethics board, and under a data-sharing agreement to ensure confidentiality and appropriate use.

Shared Documents
STUDY PROTOCOL, CSR
Time Frame
Individual participant data will be made available beginning 6 months after publication of the main study results and will remain accessible. Data requests during this time will be reviewed and approved by the principal investigator and ethics board, subject to a data use agreement.
Access Criteria
De-identified individual participant data (IPD) will be made publicly available via a trusted data repository (e.g., Figshare) beginning 6 months after publication. No specific request or proposal is required for access. Users will be able to freely download the dataset under a standard data use license (e.g., Creative Commons Attribution \[CC BY 4.0\]). All shared data will be stripped of personal identifiers to protect participant confidentiality. A link to the dataset will be provided in the publication and on institutional or project websites.

Locations